Vaccine For Non-Hodgkin’s Lymphoma

Recommend to others!

Recent researches are successful in making a breakthrough by formulating a vaccine for certain malignancies such as the Human Papilloma Virus (HPV) which can cause cervical cancer. Today, a new vaccine is discovered to be effective against non-hodgkin’s lymphoma for dogs, according to a new research.

The research from the University of Pennsylvania’s schools of Medicine and Veterinary Medicine is triumphant in discovering the first ever veterinary vaccine for cancer of its kind which was published in the open access journal PLOS ONE. This research was conducted by several professors of various universities which includes Nicola Mason, assistant professor of medicine at Penn Vet; Robert H. Vonderheide, associate professor of hematology and oncology at the Perelman School of Medicine; and Karin U. Sorenmo, associate professor of oncology at Penn Vet; Erika Krick, Beth Overley and Thomas P. Gregor of Penn Vet and Christina M. Coughlin of the School of Medicine who as well contributed in the development of the research.

According to the National Cancer Institute, Any of a large group of cancers of lymphocytes (white blood cells). Non-Hodgkin lymphomas can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of non-Hodgkin lymphoma.

Lymphoma in dogs is similar to non-Hodgkin’s lymphoma in a man. It represents 7% of all cancers in dogs affecting 24/100,000 dogs at risk each year. Most affected dogs are between 5-9 years of age, but the disease can occur in dogs of any age.

The newly discovered cancer vaccine for dogs is thought to work by increasing the rate of survival for those dogs that had non-hodgkin’s lymphoma. In addition, the vaccine also increases the range of time that a relapse of non-hodgkin’s lymphoma can occur. The discovery of this new vaccine is a significant breakthrough which can open access for further researches that caters development of vaccines against cancer in humans.

The study involves dogs which are in the stage of clinical remission of the disease and are treated with chemotherapy. These dogs received the vaccine shots and were observed for results.

“We found that, although the vaccinated dogs still relapsed with clinical disease when they were treated with rescue chemotherapy, they had significantly increased overall survival times when compared to an unvaccinated control group. Some of these dogs are still alive and cancer free more than three years later.” Mason said.

The new study implicates that through the newly discovered vaccine, there is a greater chance that relapse can be prolonged or to an extent be prevented. In addition, supportive and other medical treatments available nowadays are still necessary in producing a more desired effect, increasing the prognosis of dogs that are having this disease.

“The results with these dogs indicate that our immunotherapy and rescue chemotherapy appear to act synergistically to prevent a second relapse — a phenomenon that has been previously recognized in human patients treated with other types of immunotherapy,” she added.




Speak Your Mind


Current day month ye@r *